AdC6-HIVgp140
- Generic Name
- AdC6-HIVgp140
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
Phase 1
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- Biological: PlaceboBiological: CH505TF gp120
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 34
- Registration Number
- NCT05182125
- Locations
- 🇿🇦
CAPRISA eThekwini CRS, Durban, South Africa
🇿🇦Emavundleni CRS, Cape Town, South Africa
🇿🇦Setshaba Research Centre CRS, Soshanguve, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath